Faricimab, a bispecific antibody that simultaneously inhibits Vascular Endothelial Growth Factor (VEGF) and Angiopoietin 2 (ANG2), has been proposed as a novel approach to treat diabetic macular edema [19]. The gene discussed is VEGFA; the disease is diabetic macular edema.